Stem cell transplantation is considered the “gold standard” procedure for the treatment of blood cancers (including leukaemia, lymphoma and myeloma) in both adults and children. Globally, over 9,000 patients per year undergo this high-risk, life-saving therapy. However, graft-versus-host disease (GVHD) occurs in 50-70% of patients, of which 20% will develop severe GVHD that is untreatable. Unfortunately, additional complications such as infection and cancer relapse are common.
Research conducted by the Transplantation Immunology laboratory focuses on improving our understanding of the pathophysiology of complications following stem cell transplantation. Using unique preclinical models combined with innovative technologies, the group aims to define the immunological mechanisms that underpin these complex disease processes, with the view of translating the basic research findings into clinical practice.
We gratefully acknowledge support from the following funding bodies:
”An integrated transcriptomic atlas: 3D UMAP visualization of alloreactive CD4 T cell migration into the gut over time following allogeneic stem cell transplantation.” doi: 10.1172/jci.insight.137990